Prof. Guido Grandi is a distinguished Italian scientist who took leading positions in industrial research. In 1987 he was appointed Head of the Biotechnology Centers (Rome and Milan, Italy) of ENIRICERCHE, the Centralized Research Company of ENI. In 1995 he became Director of the Biochemistry and Molecular Biology Department of the Vaccines Division of Chiron (Siena, Italy). When Chiron was acquired by Novartis in 2006, Prof. Grandi was appointed Senior Project Leader and Member of the Board of Directors of Novartis Vaccines and Diagnostics, Italy. In 2008 Prof. Grandi was also nominated Director of the Life Sciences Department of the National Research Council (CNR). In 2015 Prof. Grandi left Novartis to become Full Professor of Microbiology and Clinical Microbiology at Trento University, Italy. Prof. Grandi is a permanent member of the European Molecular Biology Organization (EMBO) and is member of numerous national and international scientific advisory boards. He is also the recipient of two prestigious Advanced ERC Grants from the European Community (2014-2019; 2019-2024) aiming at the exploitation of Synthetic Biology for the development of a novel vaccine platform for infectious diseases and cancer. Prof. Grandi is inventor/co-inventor of more than 500 granted international patents and of several patent applications currently under examination by EU and USA patent offices. He is author/co-author of more than 200 publications on international peer-reviewed papers, of 20 book chapters, and is editor/co-editor of three books.